Grunnleggende statistikk
| CIK | 1415684 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to MusclePharm Corp
SEC Filings (Chronological Order)
På denne siden finner du en fullstendig, kronologisk liste over SEC-arkiveringer, med unntak av eierskaps-arkiveringer som vi leverer andre steder.
| August 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 22, 2023 MusclePharm Corporation (Exact Name of Registrant as Specified in Charter) Nevada (State of Incorporation) 000-53166 77-0664193 (Commission File Number) (I.R.S. Employ |
|
| July 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 10, 2023 MusclePharm Corporation (Exact Name of Registrant as Specified in Charter) Nevada (State of Incorporation) 000-53166 77-0664193 (Commission File Number) (I.R.S. Employer |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 9, 2023 MusclePharm Corporation (Exact Name of Registrant as Specified in Charter) Nevada (State of Incorporation) 000-53166 77-0664193 (Commission File Number) (I.R.S. Employer |
|
| December 21, 2022 |
Exhibit 1 Execution Version SETTLEMENT AGREEMENT AND RELEASE BETWEEN WHITE WINSTON SELECT ASSET FUNDS, LLC AND WHITE WINSTON SELECT ASEET FUND SERIES FUND MP-18, LLC AND MUSCLEPHARM CORPORATION AND RYAN DREXLER This Settlement Agreement and Release (?Agreement?) is made by and between, on the one hand, White Winston Select Asset Funds, LLC (?White Winston?) and White Winston Select Asset Fund Series Fund MP-18, LLC (the ?Series Fund?), and, on the other, MusclePharm Corporation (?MusclePharm?) and Ryan Drexler (collectively, the ?Parties,? and each individually a ?Party?). |
|
| December 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* MusclePharm Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 627335201 (CUSIP Number) Todd M. Enright White Winston Select Asset Fund Series Fund MP-18, LLC 265 Franklin St., Suite 1702 Boston, MA 02110 |
|
| September 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 26, 2022 MusclePharm Corporation (Exact Name of Registrant as Specified in Charter) Nevada (State of Incorporation) 000-53166 77-0664193 (Commission File Number) (I.R.S. Emp |
|
| September 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 26, 2022 MusclePharm Corporation (Exact Name of Registrant as Specified in Charter) Nevada (State of Incorporation) 000-53166 77-0664193 (Commission File Number) (I.R.S. Employ |
|
| August 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 17, 2022 MusclePharm Corporation (Exact Name of Registrant as Specified in Charter) Nevada (State of Incorporation) 000-53166 77-0664193 (Commission File Number) (I.R.S. Employ |
|
| August 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 22, 2022 MusclePharm Corporation (Exact Name of Registrant as Specified in Charter) Nevada (State of Incorporation) 000-53166 77-0664193 (Commission File Number) (I.R.S. Employ |
|
| August 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-53166 CUSIP NUMBER NOTIFICATION OF LATE FILING 627335201 (Check one): ? Form 10-K ?Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-CEN ? Form N-CSR For Period Ended: June 30, 2022 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transiti |
|
| July 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported) July 22, 2022 MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdiction of incorporation) (Commission File Number) (I. |
|
| July 28, 2022 |
Separation and Release Agreement between the Company and Sabina Rizvi dated July 22, 2022 Exhibit 10.1 SEPARATION AND RELEASE AGREEMENT This Separation and Release Agreement (the ?Agreement?) is by and between Sabina Rizvi (?Employee?) and MusclePharm Corporation, a Nevada corporation (the ?Company?). WHEREAS, Employee?s status as an employee and director of the Company will end effective July 22, 2022 (the ?Termination Date?); and WHEREAS, Employee and the Company desire to assure a s |
|
| July 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported) July 7, 2022 MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdiction of incorporation) (Commission File Number) (I. |
|
| June 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 June 17, 2022 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of (Commission (I. |
|
| June 17, 2022 |
Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) MusclePharm Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Title of Each Class of Securities to be Registered Amount to be Registered (1) Proposed Maximum Offering Price per Security(2) Proposed Maximum Aggregate Offering Price(2) Amount of Registration Fee Common Stock, par value $0. |
|
| June 17, 2022 |
As filed with the Securities and Exchange Commission on June 16, 2022 As filed with the Securities and Exchange Commission on June 16, 2022 Registration No. |
|
| June 14, 2022 |
Amendment to Ryan Drexler’s Amended and Restated Employment Agreement dated June 10, 2022 Exhibit 10.7 FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT This First Amendment (this ?Amendment?) to the Amended and Restated Employment Agreement dated as of June 10, 2022 (the ?Amendment Effective Date?), is entered into between by and between MusclePharm Corporation, a Nevada corporation (the ?Company?), and Ryan Drexler (the ?Executive?). All capitalized terms used herein but n |
|
| June 14, 2022 |
Drexler August Note, as amended Exhibit 10.6 THIS NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATI |
|
| June 14, 2022 |
Drexler November Note, as amended Exhibit 10.5 THIS NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATI |
|
| June 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported) June 10, 2022 MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdiction of incorporation) (Commission File Number) (I. |
|
| June 9, 2022 |
Exhibit 10.2 EXECUTION VERSION NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO A |
|
| June 9, 2022 |
Exhibit 10.1 [*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. AMENDED AND RESTATED SECURITIES PURCHASE AGREEMENT This Amended and Restated Securities Purchase Agreement (this ?Agreement?) is dated as of June 3, 2022 by and among MusclePharm Corporation, a Nevada corporation |
|
| June 9, 2022 |
Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported) June 3, 2022 MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdiction of incorporation) (Commission File Number) (I. |
|
| June 9, 2022 |
Exhibit 10.3 EXECUTION VERSION THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR |
|
| June 9, 2022 |
Exhibit 10.4 WAIVER AND AMENDMENT This Waiver and Amendment dated as of June 3, 2022 (the ?Agreement?) is by and between MusclePharm Corporation, a Nevada corporation (the ?Company?), and the undersigned, a Purchaser (as defined below) identified on the signature pages hereto. Capitalized terms not defined herein shall have the meanings assigned to them in that certain (i) Securities Purchase Agre |
|
| May 17, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 16, 2022 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| May 17, 2022 |
Exhibit 99.1 MusclePharm Announces First Quarter 2022 Financial Results Company Revenue Increases 31% Sequentially to $13.1 Million in First Quarter of 2022 Second Consecutive Quarter of Margin Improvement Despite Industry-Wide Supply Challenges Company Triples MP Performance Energy Sales in First Quarter of 2022 from Fourth Quarter of 2021 to Over $1.1 Million; Delivers Energy Margins of 35% in F |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-53166 MusclePh |
|
| May 5, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 5, 2022 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| May 5, 2022 |
Exhibit 99.1 Correction: MusclePharm Announces Fourth Quarter and Fiscal Year 2021 Financial Results Company Delivers $10.0 Million of Net Revenue in Fourth Quarter 2021 and $50.0 Million of Net Revenue for Full Year 2021 Operating Expenses Decline $2.7 Million or 16% for Full Year 2021 Company Sells More Than 1.4 Million Cans of MP Performance Energy Since Launch; Delivers Fourth Quarter 2021 Ene |
|
| May 4, 2022 |
Exhibit 10.14 |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number ? 000-5 |
|
| May 4, 2022 |
Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries of the Registrant MusclePharm Corporation has the following subsidiary as of the date of this Annual Report on Amendment No. 1 to Form 10-K: 1. Canada MusclePharm Enterprises Corporation (2012) Ontario, Canada Registered -1- |
|
| April 28, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 April 14, 2022 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| April 28, 2022 |
Exhibit 99.1 MusclePharm Announces Fourth Quarter and Fiscal Year 2021 Financial Results Company Delivers $10.0 Million of Net Revenue in Fourth Quarter 2021 and $50.0 Million of Net Revenue for Full Year 2021 Operating Expenses Decline $2.7 Million or 16% for Full Year 2021 Company Sells More Than 1.4 Million Cans of MP Performance Energy Since Launch; Delivers Fourth Quarter 2021 Energy Margins |
|
| April 15, 2022 |
Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries of the Registrant MusclePharm Corporation has the following subsidiary as of the date of this Annual Report on Form 10-K: 1. Canada MusclePharm Enterprises Corporation (2012) Ontario, Canada Registered -1- |
|
| April 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number ? 000-53166 MusclePharm C |
|
| April 15, 2022 |
Exhibit 10.13 |
|
| April 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* MusclePharm Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 627335201 (CUSIP Number) Todd M. Enright White Winston Select Asset Fund Series Fund MP-18, LLC 265 Franklin St., Suite 1702 Boston, MA 02110 |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 000-53166 NOTIFICATION OF LATE FILING ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2021 ☐Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transition Report on Form N-SAR |
|
| March 11, 2022 |
Exhibit 10.2 FIRST AMENDMENT TO INTERCREDITOR AND SUBORDINATION AGREEMENT This FIRST AMENDMENT TO INTERCREDITOR AND SUBORDINATION AGREEMENT (this ?Amendment?), dated as of March 8, 2022, is entered into by and between Ryan Drexler, an individual (?Subordinated Creditor?), MusclePharm Corporation, a Nevada corporation (the ?Borrower?) and Empery Tax Efficient, LP, as representative on behalf of the |
|
| March 11, 2022 |
Exhibit 10.3 INTERCREDITOR AND SUBORDINATION AGREEMENT This INTERCREDITOR AND SUBORDINATION AGREEMENT is made as of October 13, 2021 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, this ?Agreement?), among RYAN DREXLER, an individual (?Subordinated Creditor?), MUSCLEPHARM CORPORATION, a Nevada corporation (?Borrower?), and EMPERY TAX EFFICIENT, LP |
|
| March 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 March 8, 2022 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| March 11, 2022 |
Exhibit 10.1 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAS BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQ |
|
| February 22, 2022 |
Exhibit 1 COMMONWEALTH OF MASSACHUSETTS SUFFOLK, SS. SUPERIOR COURT DEPT. BUSINESS LITIGATION SESSION DOCKET NO. : WHITE WINSTON SELECT ASSET : FUNDS, LLC and : 2/8/2022 WHITE WINSTON SELECT ASSET : FUND SERIES FUND MP-18, LLC, : : Plaintiffs, : : v. : VERIFIED COMPLAINT : MUSCLEPHARM CORPORATION and : RYAN DREXLER, : : Defendants. : : Plaintiffs White Winston Select Asset Funds, LLC (?WWSAF?) and |
|
| February 22, 2022 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* MusclePharm Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 627335201 (CUSIP Number) Todd M. Enright White Winston Select Asset Fund Series Fund MP-18, LLC 265 Franklin St., Suite 1702 Boston, |
|
| December 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 December 22, 2021 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| November 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-53166 Musc |
|
| November 17, 2021 |
EX-10.1 3 ex10-1.htm Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO MUSCLEPHARM CORPORATION IF PUBLICLY DISCLOSED FIRST AMENDMENT TO CONFIDENTIAL SETTLEMENT AGREEMENT THIS FIRST AMENDMENT TO CONFIDENTIAL SETTLEMENT AGREEMENT(“Amendment”) is entered into by and between |
|
| November 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2021 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report |
|
| November 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 November 15, 2021 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| November 16, 2021 |
Exhibit 99.1 MusclePharm Announces Third Quarter 2021 Financial Results Company Continues Focus on Controlling Operating Expenses with 21% Decline in Third Quarter 2021 First Production Run of MP Combat Energy Successfully Sold 100%; $30 Million of Annual Sales Expected in 2023 Company Expects Sequential Revenue Growth in Fourth Quarter 2021 from New Product Formulation and MP Energy Drink Line La |
|
| November 2, 2021 |
Exhibit 99.1 MusclePharm taps former Rockstar Energy executive to lead Product Development and National Marketing Strategy for Performance Energy beverages for MP and FitMiss brands. CALABASAS, Calif., Oct 19, 2021 (GLOBE NEWSWIRE) ? MusclePharm Corporation (OTCMKTS: MSLP), a global provider of leading sports nutrition and lifestyle branded nutritional supplements, today announced a partnership wi |
|
| November 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 October 28, 2021 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| October 19, 2021 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of October 13, 2021, between MusclePharm Corporation, a Nevada corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the terms and condition |
|
| October 19, 2021 |
Exhibit 10.2 PLEDGE AND SECURITY AGREEMENT PLEDGE AND SECURITY AGREEMENT, dated as of October 13, 2021 (this ?Agreement?), made by MusclePharm Corporation, a Nevada corporation (the ?Company?), each Subsidiary of the Company listed on the signature pages hereto (together with the Company, and each additional Person that becomes party to this Agreement by executing a Security Agreement Supplement i |
|
| October 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 October 13, 2021 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| October 19, 2021 |
Form of Senior Note issued in the October 2021 Financing EX-4.2 3 ex4-2.htm Exhibit 4.2 EXECUTION VERSION THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE |
|
| October 19, 2021 |
Form of Warrant issued in the October 2021 Financing EX-4.1 2 ex4-1.htm Exhibit 4.1 EXECUTION VERSION NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EX |
|
| October 15, 2021 |
October 15, 2021 BY EDGAR SUBMISSION Messrs. Pavot and O?Brien Office of Life Sciences Division of Corporation Finance U.S. Securities & Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: MusclePharm Corp Form 10-K filed March 29, 2021 Form 10-Q filed August 16, 2021 File No. 0-53166 Dear Messrs. Pavot and O?Brien: Set forth below are the responses of MusclePharm Corporation (the ?Com |
|
| October 13, 2021 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 October 13, 2021 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| October 13, 2021 |
MusclePharm Announces Closing of $7.0 Million Senior Secured Notes Offering Exhibit 99.1 MusclePharm Announces Closing of $7.0 Million Senior Secured Notes Offering CALABASAS, Calif., October, 13, 2021 (GLOBE NEWSWIRE) ? MusclePharm Corporation (OTCMKTS: MSLP), a global provider of leading sports nutrition & lifestyle branded nutritional supplements, today announced that it has entered into definitive agreements with accredited institutional investors for gross proceeds o |
|
| October 1, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 September 23, 2021 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 August 16, 2021 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| August 16, 2021 |
Letter Agreement, dated May 12, 2021 by and between MusclePharm Corporation and Joseph Cannata Exhibit 10.1 AGREEMENT This Agreement (this ?Agreement?) is entered into as of May 12, 2021 (the ?Effective Date?) by MusclePharm Corporation, a Nevada corporation (the ?Company?), and Joseph Cannata, a California resident (?Service Provider?). The Company and the Service Provider are referred to in this Agreement individually as a ?party? and collectively as the ?parties.? Recitals WHEREAS, The C |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-53166 MusclePha |
|
| August 16, 2021 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 MusclePharm Increases Sequential Sales in Second Quarter 2021 Despite Continued Industry Wide Supply Chain Challenges Company Delivers 14% Sequential Net Revenue Growth in Second Quarter 2021 Operating Expenses Decline $0.7 Million or 15% in Second Quarter 2021 Company Prepares for Official MP Performance Energy Launch in August 2021 and Expects Energy Business in |
|
| July 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 July 14, 2021 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| June 10, 2021 |
Letter regarding change in certifying accountant. Exhibit 16 June 10, 2021 Securities and Exchange Commission Washington, D.C. 20549 Commissioners: We have read MusclePharm Corporation?s statements included under Item 4.01(a) of its Form 8-K filed on June 10, 2021 and we agree with such statements concerning our firm. |
|
| June 10, 2021 |
Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 June 4, 2021 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| June 2, 2021 |
MusclePharm Appoints New Independent Board Member Exhibit 99.1 MusclePharm Appoints New Independent Board Member CALABASAS, Calif., June 1, 2021 (GLOBE NEWSWIRE) ? MusclePharm Corporation (OTCMKTS: MSLP), a global provider of leading sports nutrition & lifestyle branded nutritional supplements, today reported the appointment of Paul Karr as a new independent Board Member. With a history in financial reporting, issue resolution, and internal contr |
|
| June 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 June 1, 2021 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| May 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 24, 2021 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| May 24, 2021 |
Letter Agreement, dated April 1, 2021 by and between MusclePharm Corporation and Sabina Rizvi Exhibit 10.1 April 1, 2021 Dear Sabina, Welcome to MusclePharm. We are excited to have you on the team and are pleased to confirm your offer of employment as President and Chief Financial Officer. Details of the offer are as follows: ? Start Date: April 5, 2021 ? Reporting To: Ryan Drexler ? Salary: You will be paid annually in the amount of $450,000, less applicable taxes and withholdings. After |
|
| May 24, 2021 |
Exhibit 99.1 MusclePharm Delivers Profitable First Quarter 2021 Despite Industry Wide Supply Shortages Operating expenses declined ~$0.8 million or 20% in First Quarter 2021 March and April sales increased compared to prior year periods Company closed deal with major distributor ahead of MP Performance Energy beverages launch in Summer 2021 CALABASAS, Calif., May 24, 2021 (GLOBE NEWSWIRE) ? Muscle |
|
| May 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2021 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-53166 Musc |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 12, 2021 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| May 17, 2021 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 MusclePharm taps former Rockstar Energy executive to build National Distribution Network and Sales Team for MP Performance Energy beverages CALABASAS, Calif., May 13, 2021 (GLOBE NEWSWIRE) — MusclePharm Corporation (OTCMKTS: MSLP), a global provider of leading sports nutrition and lifestyle branded nutritional supplements, today announced a partnership with former |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-CEN [ ] Form N-CSR For Period Ended: March 31, 2021 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ |
|
| April 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 April 1, 2021 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| March 31, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 March 30, 2021 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| March 31, 2021 |
Exhibit 99.1 MusclePharm Announces Record Breaking Fourth Quarter and Fiscal Year 2020 Financial Results; Primed for Return to Growth Full Year Gross Margins Improve over 1,900 basis points to 30% Operating Expenses Decline $6.8 million or over 29% Plans to Leverage Leading Brand by Entering New Categories to return to Growth CALABASAS, Calif., March 30, 2021 (GLOBE NEWSWIRE) — MusclePharm Corpora |
|
| March 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number ? 000-53166 MusclePha |
|
| March 29, 2021 |
Exhibit 10.23 SETTLEMENT AGREEMENT AND MUTUAL RELEASE This Settlement Agreement and Mutual General Release (the ?Agreement?) is entered into as of December 11, 2020 (the ?Effective Date?) by and between Plaintiff Excelsior Nutrition, Inc. (?Plaintiff? or ?4Excelsior?) and Defendant MusclePharm Corporation (?Defendant? or ?MusclePharm?). Excelsior and MusclePharm are referred to individually as a ? |
|
| March 29, 2021 |
EX-10.15 2 ex10-15.htm Exhibit 10.15 NOTE SBA Loan # SBA Loan Name MusclePharm Corporation Date 04/27/2020 Loan Amount $964,910.00 Interest Rate 1% fixed Borrower MusclePharm Corporation Lender Harvest Small Business Finance, LLC 1. PROMISE TO PAY: In return for the Loan, Borrower promises to pay to the order of Lender the amount of nine hundred sixty-four thousand nine hundred ten and 00/100 Doll |
|
| March 29, 2021 |
Subsidiaries of the Registrant. Exhibit 21.1 To Annual Report Form 10-K For the Year ended December 31, 2021 Subsidiaries of the Registrant Canada MusclePharm Enterprises Corporation (2012) Ontario, Canada Registered MP Holding Ireland, LLC (2014) Delaware LLC MusclePharm Holdings Ireland (2014) Ireland Registration Isle of Man Managed Company MusclePharm Ireland (2014) Ireland Registration MusclePharm Australia PTY LTD (2015) A |
|
| January 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 January 19, 2021 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| January 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 December 31, 2020 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| December 22, 2020 |
Entry into a Material Definitive Agreement - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 December 16, 2020 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| December 3, 2020 |
Exhibit 10.2 Sixth Amended and Restated Security Agreement This Sixth Amended and Restated Security Agreement (this “Agreement”), dated as of November 29, 2020, is entered into between Ryan Drexler, an individual (“Grantee”), and MusclePharm Corporation, a Nevada corporation, as grantor (“Grantor”). Background WHEREAS, Grantor and Grantee previously entered into (i) a convertible secured promissor |
|
| December 3, 2020 |
Exhibit 10.1 THIS NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATI |
|
| December 3, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 November 29, 2020 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| December 2, 2020 |
Exhibit 99.1 THIS NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATI |
|
| December 2, 2020 |
Exhibit 99.2 Sixth Amended and Restated Security Agreement This Sixth Amended and Restated Security Agreement (this “Agreement”), dated as of November 29, 2020, is entered into between Ryan Drexler, an individual (“Grantee”), and MusclePharm Corporation, a Nevada corporation, as grantor (“Grantor”). Background WHEREAS, Grantor and Grantee previously entered into (i) a convertible secured promissor |
|
| December 2, 2020 |
MSLP / MusclePharm Corp. / Drexler Ryan Charles Activist Investment CUSIP No. 627335201 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* MUSCLEPHARM CORPORATION (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 627335201 (CUSIP Number) Ryan Charles Drexler c/o MusclePharm Corporation 4500 Park Granada, Suite 202 Calabasas, C |
|
| December 1, 2020 |
Exhibit 99.1 Contact: John Mills, Managing Partner ICR, Inc. 646-277-1254 [email protected] [email protected] MUSCLEPHARM ANNOUNCES THIRD QUARTER 2020 FINANCIAL RESULTS Company Restructuring Generating Positive Results as Third Quarter 2020 Gross Margins improve to 31% and Operating Expenses Decrease by 22% Calabasas, CA—December 1, 2020—MusclePharm Corp Inc. (OTCQB: MSLP), a global provider |
|
| December 1, 2020 |
Results of Operations and Financial Condition, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 December 1, 2020 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| November 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: March 31, 2020 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 000-53166 MusclePharm Cor |
|
| November 24, 2020 |
Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO MUSCLEPHARM CORPORATION IF PUBLICLY DISCLOSED CONFIDENTIAL SETTLEMENT AGREEMENT NBF Holdings Canada Inc. v. MusclePharm Corporation, Case No. 2:20-cv-01946-SVW PARTIES THIS CONFIDENTIAL SETTLEMENT AGREEMENT (“Agreement”) i |
|
| November 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: September 30, 2020 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 000-53166 MusclePharm |
|
| November 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: June 30, 2020 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 000-53166 MusclePharm Corp |
|
| November 3, 2020 |
MSLP / MusclePharm Corp. / WYNNEFIELD PARTNERS SMALL CAP VALUE LP I - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 12) Under the Securities Exchange Act of 1934 MUSCLEPHARM CORP. ‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾ (Name of Issuer) Common Stock, $0.001 par value ‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾ |
|
| October 28, 2020 |
MSLP / MusclePharm Corp. / WYNNEFIELD PARTNERS SMALL CAP VALUE LP I - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 11) Under the Securities Exchange Act of 1934 MUSCLEPHARM CORP. ‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾ (Name of Issuer) Common Stock, $0.001 par value ‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾ |
|
| October 21, 2020 |
Exhibit 10.1 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAS BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQ |
|
| October 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 October 15, 2020 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| October 21, 2020 |
Exhibit 10.2 Fifth Amended and Restated Security Agreement This Fifth Amended and Restated Security Agreement (this “Agreement”), dated as of October 15, 2020, is entered into between Ryan Drexler, an individual (“Grantee”), and MusclePharm Corporation, a Nevada corporation, as grantor (“Grantor”). Background WHEREAS, Grantor and Grantee previously entered into (i) a secured revolving promissory n |
|
| October 1, 2020 |
Entry into a Material Definitive Agreement - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 September 25, 2020 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| August 27, 2020 |
Exhibit 10.2 Fourth Amended and Restated Security Agreement This Fourth Amended and Restated Security Agreement (this “Agreement”), dated as of August 21, 2020, is entered into between Ryan Drexler, an individual (“Grantee”), and MusclePharm Corporation, a Nevada corporation, as grantor (“Grantor”). Background WHEREAS, Grantor and Grantee previously entered into (i) a secured revolving promissory |
|
| August 27, 2020 |
Exhibit 10.1 THIS NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATI |
|
| August 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 August 21, 2020 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| August 25, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number – 000-53166 MusclePharm C |
|
| August 25, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: September 30, 2019 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 000-53166 MusclePharm Cor |
|
| August 25, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: June 30, 2019 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 000-53166 MusclePharm Corporat |
|
| August 25, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: March 31, 2019 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 000-53166 MusclePharm Corpora |
|
| July 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 July 22, 2020 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| July 13, 2020 |
MSLP / MusclePharm Corp. / WYNNEFIELD PARTNERS SMALL CAP VALUE LP I - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 10) Under the Securities Exchange Act of 1934 MUSCLEPHARM CORP. ‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾ (Name of Issuer) Common Stock, $0.001 par value ‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾ |
|
| May 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 14, 2020 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| May 7, 2020 |
SEVERANCE AND RELEASE AGREEMENT Exhibit 10.1 SEVERANCE AND RELEASE AGREEMENT MusclePharm Corporation its subsidiaries, parents, predecessors, successors and affiliates (the “Company”) and Brian Casutto, Employee’s heirs, executors, administrators, successors, and assigns (collectively referred to throughout this Agreement as “Employee”), agree that: 1. Last Day of Employment. Employee's last day of employment with the Company wa |
|
| May 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 1, 2020 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| April 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 April 20, 2020 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| December 19, 2019 |
Exhibit 10.1 December 13, 2019 Troy Bolotnick 22512 Cantlay Street West Hills, CA 91307 Dear Troy, We are pleased to offer you the position of Chief Operating Officer. Your annual base compensation will remain $300,000 which will be paid to you through payroll on a semi-monthly basis one pay period in arrears. You will also be eligible to participate in MusclePharm’s Discretionary Bonus Program an |
|
| December 19, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 December 13, 2019 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| November 8, 2019 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* MusclePharm Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 627335201 (CUSIP Number) Todd M. Enright White Winston Select Asset Fund Series Fund MP-18, LLC 265 Franklin St., Suite 1702 Boston, |
|
| October 10, 2019 |
Exhibit 10.2 Security Agreement This Security Agreement (this “Agreement”), dated as of October 4, 2019, is entered into between Ryan Drexler, an individual (“Grantee”), and MusclePharm Corporation, a Nevada corporation, as grantor (“Grantor”). Background WHEREAS, Grantor and Grantee have entered into a Secured Revolving Promissory Note dated as of even date herewith (as amended, restated, or othe |
|
| October 10, 2019 |
Exhibit 99.1 Ryan Drexler October 4, 2019 Crossroads Financial, LLC 6001 Broken Sound Parkway, Suite 620 Boca Raton, Florida 33487 Re: Promissory Note Ladies and Gentlemen: Reference is made to that certain Subordination Agreement, dated September 30, 2017 (as amended, the “Subordination Agreement”), by and between Ryan Drexler (“Creditor”) and Crossroads Financial, LLC (“Lender”). Capitalized ter |
|
| October 10, 2019 |
SECURED REVOLVING PROMISSORY NOTE Exhibit 10.1 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAS BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQ |
|
| October 10, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 October 4, 2019 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| October 7, 2019 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* MusclePharm Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 627335201 (CUSIP Number) Todd M. Enright White Winston Select Asset Fund Series Fund MP-18, LLC 265 Franklin St., Suite 1702 Boston, |
|
| September 18, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 September 16, 2019 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| September 18, 2019 |
NOTICE OF CONVERTIBLE SECURED PROMISSORY NOTE PARTIAL CONVERSION Exhibit 99.12 NOTICE OF CONVERTIBLE SECURED PROMISSORY NOTE PARTIAL CONVERSION THIS NOTICE OF CONVERTIBLE SECURED PROMISSORY NOTE PARTIAL CONVERSION (this “Notice”), dated September 16, 2019 (the “Notice Date”), is being delivered to MusclePharm Corporation, a Nevada corporation (the “Company”), by Ryan Drexler (the “Noteholder”), pursuant to that certain Amended and Restated Convertible Secured P |
|
| September 18, 2019 |
MSLP / MusclePharm Corp. / Drexler Ryan Charles - SC 13D/A Activist Investment CUSIP No. 627335201 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* MUSCLEPHARM CORPORATION (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 627335201 (CUSIP Number) Ryan Charles Drexler c/o MusclePharm Corporation 4400 W. Vanowen Street Burbank, CA 91505 |
|
| August 22, 2019 |
MSLP / MusclePharm Corp. / WYNNEFIELD PARTNERS SMALL CAP VALUE LP I - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 9) Under the Securities Exchange Act of 1934 MUSCLEPHARM CORP. ‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾ (Name of Issuer) Common Stock, $0.001 par value ‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾ |
|
| August 5, 2019 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* MusclePharm Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 627335201 (CUSIP Number) Todd M. Enright White Winston Select Asset Fund Series Fund MP-18, LLC 265 Franklin St., Suite 1702 Boston, |
|
| June 6, 2019 |
Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 June 6, 2019 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| June 6, 2019 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 31, 2019 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| June 6, 2019 |
Exhibit 16.1 |
|
| May 16, 2019 |
MSLP / MusclePharm Corp. NT 10-Q PRIMARY DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐Form 10-K ☐Form 20-F ☐Form 11-K ☒Form 10-Q ☐ Form N-SAR ☐Form N-CSR For Period Ended: March 31, 2019 ☐Transition Report on Form 10-K ☐Transition Report on Form 20-F ☐Transition Report on Form 11-K ☐Transition Report on Form 10-Q ☐Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| May 1, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 April 30, 2019 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| May 1, 2019 |
Exhibit 99.1 MusclePharm Hires Former General Electric Veteran to Head Operations Strengthens Executive Leadership Team with Appointment of Alberto Andrade as Chief Operating Officer Burbank, CA – (April 30, 2019) - MusclePharm® Corporation (OTCQB: MSLP) (“MusclePharm” or the “Company”), a scientifically driven, performance-lifestyle sports nutrition company, today announced that it has finalized |
|
| May 1, 2019 |
Exhibit 10.1 April 10, 2019 Alberto Andrade 26 Malibu Irvine, CA 92602 Dear Alberto, We are pleased to offer you the position of Chief Operating Officer. Your starting annual base compensation will be $350,000 which will be paid to you through payroll on a semi-monthly basis one pay period in arrears. You will also be eligible to participate in MusclePharm’s Discretionary Bonus Program and are eli |
|
| April 1, 2019 |
MSLP / MusclePharm Corp. NOTIFICATION OF LATE FIING OMB APPROVAL OMB Number: 3235-0058 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 14, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 March 8, 2019 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| March 12, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 8) Under the Securities Exchange Act of 1934 MUSCLEPHARM CORP. ‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾ (Name of Issuer) Common Stock, $0.001 par value ‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾ |
|
| December 13, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 December 7, 2018 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| December 6, 2018 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 November 30, 2018 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| November 14, 2018 |
MSLP / MusclePharm Corp. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53166 MusclePharm |
|
| November 13, 2018 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 November 13, 2018 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| November 13, 2018 |
Exhibit 99.1 MusclePharm Corporation Reports Third Quarter 2018 Financial Results Achieves fourth consecutive quarter of sequential revenue growth Conference call begins at 4:30 p.m. Eastern time today BURBANK, Calif. (November 13, 2018) – MusclePharm® Corporation (OTCQB: MSLP) (“MusclePharm” or the “Company”), a scientifically driven, performance-lifestyle sports nutrition company, reports financ |
|
| October 26, 2018 |
MSLP / MusclePharm Corp. PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| October 4, 2018 |
Exhibit 16.1 October 4, 2018 Securities and Exchange Commission Washington, D.C. 20549 Commissioners: We have read MusclePharm Corporation’s statements included under Item 4.01 of its Form 8-K filed on October 4, 2018 and we agree with such statements concerning our firm. /s/EKS&H LLLP EKS&H LLLP |
|
| October 4, 2018 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 October 1, 2018 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| September 10, 2018 |
MSLP / MusclePharm Corp. WITHDRAWAL REQUEST MusclePharm Corporation 4400 Vanowen Street Burbank, CA 91505 September 10, 2018 VIA EDGAR AND FEDEX Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| September 4, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 September 4, 2018 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| August 24, 2018 |
Amendment No. 1 to Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* MusclePharm Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 627335201 (CUSIP Number) Todd M. Enright White Winston Select Asset Fund Series Fund MP-18, LLC 265 Franklin |
|
| August 14, 2018 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 August 14, 2018 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| August 14, 2018 |
Exhibit 99.1 MusclePharm Corporation Reports Second Quarter 2018 Financial Results Achieves third consecutive quarter of sequential revenue growth Conference call begins at 4:30 p.m. Eastern time today BURBANK, Calif. (August 14, 2018) – MusclePharm® Corporation (OTCQB: MSLP) (“MusclePharm” or the “Company”), a scientifically driven, performance-lifestyle sports nutrition company, reports financia |
|
| August 14, 2018 |
MSLP / MusclePharm Corp. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53166 MusclePharm Corp |
|
| July 25, 2018 |
MSLP / MusclePharm Corp. / WYNNEFIELD PARTNERS SMALL CAP VALUE LP I - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 7*) Under the Securities Exchange Act of 1934 MUSCLEPHARM CORP. ‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾ (Name of Issuer) Common Stock, $0.001 par value ‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾ |
|
| July 25, 2018 |
Wynnefield Capital, Inc. 450 Seventh Avenue, Suite 509 New York, NY 10123 EXHIBIT-99.2 Wynnefield Capital, Inc. 450 Seventh Avenue, Suite 509 New York, NY 10123 July 23, 2018 Board of Directors MusclePharm Corp. 4400 Vanowen Street 91505 Burbank, CA Attention: Bill Bush and Ryan Drexler FOR DISTRIBUTION TO THE BOARD OF DIRECTORS VIA EMAIL, FEDEX, US MAIL Dear Board of Directors, It is well known in informed institutional investment circles that Wynnefield Capital has ma |
|
| July 24, 2018 |
Wynnefield Capital, Inc. 450 Seventh Avenue, Suite 509 New York, NY 10123 EXHIBIT-99.2 Wynnefield Capital, Inc. 450 Seventh Avenue, Suite 509 New York, NY 10123 July 23, 2018 Board of Directors MusclePharm Corp. 4400 Vanowen Street 91505 Burbank, CA Attention: Bill Bush and Ryan Drexler FOR DISTRIBUTION TO THE BOARD OF DIRECTORS VIA EMAIL, FEDEX, US MAIL Dear Board of Directors, It is well known in informed institutional investment circles that Wynnefield Capital has ma |
|
| July 24, 2018 |
MSLP / MusclePharm Corp. / WYNNEFIELD PARTNERS SMALL CAP VALUE LP I - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 7) Under the Securities Exchange Act of 1934 MUSCLEPHARM CORP. ‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾ (Name of Issuer) Common Stock, $0.001 par value ‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾ |
|
| June 29, 2018 |
SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 MusclePharm Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 627335201 (CUSIP Number) Todd M. Enright White Winston Select Asset Fund Series Fund MP-18, LLC 265 Franklin St., Suite 1702 Boston, MA 02110 801-938-754 |
|
| May 15, 2018 |
MSLP / MusclePharm Corp. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53166 MusclePharm Cor |
|
| May 14, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 14, 2018 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| May 14, 2018 |
Exhibit 99.1 MusclePharm Corporation Reports First Quarter 2018 Financial Results Advances toward profitability with second consecutive quarter of sequential revenue growth and narrowed operating loss Conference call begins at 4:30 p.m. Eastern time today BURBANK, Calif. (May 14, 2018) – MusclePharm® Corporation (OTC/QB: MSLP) (“MusclePharm” or the “Company”), a scientifically driven, performance- |
|
| April 2, 2018 |
MSLP / MusclePharm Corp. ANNUAL REPORT (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year ended December 31, 2017 Commission File Number – 000-53166 MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 77-0664193 (State or other jurisdiction of incorporation or organiza |
|
| April 2, 2018 |
To Annual Report Form 10-K For the Year ended December 31, 2017 Subsidiaries of the Registrant Exhibit 21.1 To Annual Report Form 10-K For the Year ended December 31, 2017 Subsidiaries of the Registrant Canada MusclePharm Enterprises Corporation (2012) Ontario, Canada Registered MP Holding Ireland, LLC (2014) Delaware LLC MusclePharm Holdings Ireland (2014) Ireland Registration Isle of Man Managed Company MusclePharm Ireland (2014) Ireland Registration MP DO Brazil Acquisition, LLC (2014) D |
|
| April 2, 2018 |
EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.17 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT ("Agreement") is made and entered as of March , 2018 and effective as of January 1, 2018 (the "Effective Date"), by and between MusclePharm Corporation, a Nevada Corporation (the "Company"), and Brian Casutto, an individual ("Executive"). The Company and Executive are sometimes referred to herein as a "party" or colle |
|
| April 2, 2018 |
INDUSTRIAL LEASE BACKLOT BURBANK PSIP SN BURBANK LLC MUSCLEPHARM CORPORATION TABLE OF CONTENTS Exhibit 10.16 INDUSTRIAL LEASE BACKLOT BURBANK Between PSIP SN BURBANK LLC as Landlord and MUSCLEPHARM CORPORATION as Tenant TABLE OF CONTENTS Page 1. PREMISES 1 2. TERM 2 3. RENT 2 4. PREPAID RENT 6 5. SECURITY DEPOSIT 6 6. USE OF THE PREMISES AND BUILDING FACILITIES 7 7. SIGNAGE 8 8. PERSONAL PROPERTY TAXES 8 9. PARKING 8 10. UTILITIES 8 11. MAINTENANCE 8 12. ALTERATIONS 9 13. RELEASE AND INDEMN |
|
| March 28, 2018 |
EX-99.1 2 mslpex991.htm PRESS RELEASE Exhibit 99.1 MusclePharm Corporation Reports 2017 Fourth Quarter and Full Year Financial Results Fourth quarter revenue increases and operating loss narrows compared with the third quarter as company makes progress toward sustained profitable growth Conference call begins at 4:30 pm Eastern time today BURBANK, Calif. (March 28, 2018) – MusclePharm® Corporation |
|
| March 28, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 March 28, 2018 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| March 1, 2018 |
Blueprint Exhibit Transaction Bonus Agreement This Transaction Bonus Agreement (the ?Agreement?) is entered into by and between Ryan Drexler (the ?Equity Holder?) and MusclePharm Corporation, a Nevada corporation headquartered at 4400 Vanowen Street, Burbank, CA 91505 (the ?Company?) and shall become effective immediately as of the date on which the Equity Holder signs below. |
|
| March 1, 2018 |
Blueprint Exhibit 10.1 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (?Agreement?) is made and entered into as of the 1st day of February, 2018 (the ?Effective Date?), by and between MusclePharm Corporation, a Nevada corporation headquartered at 4400 Vanowen Street, Burbank, CA 91505 (?Company?) and Ryan Drexler (?Executive?). Until th |
|
| March 1, 2018 |
Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 February 26, 2018 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| January 22, 2018 |
Blueprint Musclepharm Corporation 4400 Vanowen Street Burbank, CA 91505 (303) 396-6100 January 22, 2018 BY EDGAR Securities and Exchange Commission Office of Global Security Risk Division of Corporation Finance 100 F Street, N. |
|
| January 10, 2018 |
Blueprint Musclepharm Corporation 4400 Vanowen Street Burbank, CA 91505 (303) 396-6100 January 10, 2018 BY EDGAR Securities and Exchange CommissionOffice of Global Security Risk Division of Corporation Finance 100 F Street, N. |
|
| January 3, 2018 |
MSLP / MusclePharm Corp. / WYNNEFIELD PARTNERS SMALL CAP VALUE LP I - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 6) Under the Securities Exchange Act of 1934 MUSCLEPHARM CORP. ‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾ (Name of Issuer) Common Stock, $0.001 par value ‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾‾ |
|
| December 19, 2017 |
Submission of Matters to a Vote of Security Holders Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 December 15, 2017 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| December 4, 2017 |
MSLP / MusclePharm Corp. DEFA14A Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rul |
|
| November 15, 2017 |
MSLP / MusclePharm Corp. DEFA14A Backend Error |
|
| November 14, 2017 |
Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 September 15, 2017 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| November 14, 2017 |
MSLP / MusclePharm Corp. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2017 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53166 MusclePharm |
|
| November 9, 2017 |
MSLP / MusclePharm Corp. / Drexler Ryan Charles - SC 13D/A Activist Investment CUSIP No. 627335201 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* MUSCLEPHARM CORP. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 627335201 (CUSIP Number) Ryan Charles Drexler c/o MusclePharm Corp. 4721 Ironton Street, Building A Denver, CO 80239 with |
|
| November 8, 2017 |
MSLP / MusclePharm Corp. DEF 14A Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, |
|
| November 8, 2017 |
EX-99.1 5 mslpex991.htm SUBORDINATION AGREEMENT Exhibit 99.1 SUBORDINATION AGREEMENT Crossroads Financial Group, LLC c/o The Forumat Stonecrest, LLC 11220 Elm Lane, Suite 200 Charlotte, NC 28277 Gentlemen: The undersigned, Ryan Drexler with an address at (hereinafter referred to as the "Creditor"), represents that MusclePharm Corporation and/or Canada MusclePharm Enterprises Corp. (hereinafter col |
|
| November 8, 2017 |
FIRST AMENDMENT TO SUBORDINATION AGREEMENT Blueprint Exhibit 99.2 FIRST AMENDMENT TO SUBORDINATION AGREEMENT This First Amendment to Subordination Agreement (this ?Amendment?) is made as of November 3, 2017, by and between (a) CROSSROADS FINANCIAL GROUP, LLC, a North Carolina limited liability company (the ?Lender?) and (b) Ryan Drexler, an individual (the ?Creditor?). Recitals A. MusclePharm Corporation, a Nevada corporation (the ?Musclep |
|
| November 8, 2017 |
Amended and Restated Convertible Secured Promissory Note Blueprint Exhibit 10.1 THIS NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A |
|
| November 8, 2017 |
Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 November 3, 2017 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| November 8, 2017 |
Third Amended and Restated Security Agreement Blueprint Exhibit 10.2 Third Amended and Restated Security Agreement This Third Amended and Restated Security Agreement (this ?Agreement?), dated as of November 3, 2017, is entered into between Ryan Drexler, an individual (?Grantee?), and MusclePharm Corporation, a Nevada corporation, as grantor (?Grantor?). Background WHEREAS, Grantor and Grantee previously entered into (i) a Convertible Secured |
|
| November 8, 2017 |
Blueprint Exhibit 10.3 RESTRUCTURING AGREEMENT This Restructuring Agreement (the ?Agreement?) is made as of November 3, 2017, by and between Ryan Drexler, an individual (?Drexler?) and MusclePharm Corporation, a Nevada corporation (the ?Company?). Recitals WHEREAS, the Company previously issued to Drexler (i) a convertible secured promissory note dated as of December 7, 2015, and amended as of Jan |
|
| November 1, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 5) Under the Securities Exchange Act of 1934 MUSCLEPHARM CORP. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 627335201 (CUSIP Number) Wynnefield Partners Small Cap Value, L.P. I 450 Seventh Avenue, Suite 509 New York, New York 10123 Attention: Mr. Nelson Obus Copy |
|
| October 27, 2017 |
MSLP / MusclePharm Corp. / Amerop Holdings, Inc. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* MusclePharm Corporation (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 627335201 (CUSIP Number) Leonard P. Wessell III President Amerop Holdings, Inc. 1800 Broadway, Suite 100 Boulder, CO 80302 (303) 93 |
|
| October 18, 2017 |
Exhibit B Gil B. Selinger (303) 894-4478 [email protected] September 11, 2017 Sent via E-Mail MusclePharm Corporation Board of Directors 4721 Ironton St. # A, Denver, CO 80239 Dear Sirs, This law firm represents Amerop Holdings, Inc., a Colorado corporation, and its affiliates ("Amerop") in their corporate and securities matters. Amerop is the beneficial owner of approximately 15.15% of the issu |
|
| October 18, 2017 |
Amerop Holdings, Inc. 1800 Broadway, Suite 100 Boulder, CO 80302 October 17, 2017 Exhibit A Amerop Holdings, Inc. 1800 Broadway, Suite 100 Boulder, CO 80302 October 17, 2017 MusclePharm Corporation 4791 Ironton Street, Unit A Denver, CO 80239 Attention: Special Committee of the Board of Directors Members of the Special Committee: Amerop Holdings, Inc. (“Amerop”), the largest stockholder of MusclePharm Corporation (the “Company”), believes that the Company is an outstanding spor |
|
| October 18, 2017 |
MSLP / MusclePharm Corp. / Amerop Holdings, Inc. - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 MusclePharm Corporation (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 627335201 (CUSIP Number) Leonard P. Wessell III President Amerop Holdings, Inc. 1800 Broadway, Suite 100 Boulder, CO 80302 (303) 938-0507 (Name, Address |
|
| October 10, 2017 |
Blueprint Exhibit 10.1 LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT is entered into as of October 6, 2017 by and between MusclePharm Corporation, a Nevada Corporation (with Federal Tax Identification # 77-0664193) and Canada MusclePharm Enterprises Corp., a Canada Corporation (with Business #80389 8915 RC0001), (individually or collectively, ?Borrower?), and Crossroads Financial Gr |
|
| October 10, 2017 |
Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 October 6, 2017 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| September 8, 2017 |
Blueprint Exhibit 10.1 INDEMNIFICATION AGREEMENT This Indemnification Agreement (this ?Agreement?) is made as of , , by and between MusclePharm Corporation, a Nevada corporation (the ?Company?), and (?Indemnitee?). WITNESSETH: WHEREAS, highly competent persons have become more reluctant to serve publicly traded corporations as directors, officers or in other capacities unless they are provided wit |
|
| September 8, 2017 |
MusclePharm CURRENT REPORT (Current Report/Significant Event) Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 September 6, 2017 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| September 8, 2017 |
Untitled Document Exhibit 99.1 |
|
| September 8, 2017 |
Exhibit 99.6 George W. Shuster Jr. +1 617 526 6572 (t) +1 617 526 5000 (f) [email protected] September 5, 2017 By Email ([email protected]) Michael Littenberg Ropes & Gray LLP 1211 Avenue of the Americas New York, NY 10036-8704 Re: MusclePharm Corporation / Ryan Drexler Dear Michael: As you know, we represent Ryan Drexler in regards to his investment in your client, Musc |
|
| September 8, 2017 |
MSLP / MusclePharm Corp. / Drexler Ryan Charles - SC 13D/A Activist Investment CUSIP No. 627335201 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* MUSCLEPHARM CORP. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 627335201 (CUSIP Number) Ryan Charles Drexler c/o MusclePharm Corp. 4721 Ironton Street, Building A Denver, CO 80239 with |
|
| August 15, 2017 |
MusclePharm Reports 2017 Second Quarter Financial Results Blueprint Exhibit 99.1 MusclePharm Reports 2017 Second Quarter Financial Results DENVER, August 14, 2017 - MusclePharm Corporation (MSLP) ("MusclePharm" or the "Company") (OTCQB: MSLP), a scientifically-driven, performance lifestyle sports nutrition company, today announced financial results for the second quarter ended June 30, 2017. Operational and Financial Highlights for Second Quarter 2017 (a |
|
| August 15, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 August 14, 2017 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| August 14, 2017 |
MSLP / MusclePharm Corp. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2017 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53166 MusclePharm Corp |
|
| August 14, 2017 |
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.1 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into as of the day of November 2016 (the “Amendment Date”), by and between MusclePharm Corporation, a Nevada corporation headquartered at 4721 Ironton Street, Building A, Denver, Colorado 80239 (“Company”) and Ryan Drexler (“Executive”). As use |
|
| August 3, 2017 |
Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 July 28, 2017 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| July 31, 2017 |
Secured Demand Promissory Note EX-10.1 2 mslpex101.htm SECURED DEMAND PROMISSORY NOTE, DATED JULY 24, 2017, BETWEEN MUSCLEPHARM CORPORATION AND RYAN DREXLER Exhibit 10.1 Secured Demand Promissory Note $1,000,000.00 July 27, 2017 DPN-1 Denver, Colorado For value received, MusclePharm Corporation, a Nevada corporation (the “Company”), promises to pay to Ryan Drexler or his assigns (the “Holder”) the principal sum of One Million D |
|
| July 31, 2017 |
MusclePharm CURRENT REPORT (Current Report/Significant Event) Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 July 27, 2017 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| July 31, 2017 |
Second Amended and Restated Security Agreement EX-10.2 3 mslpex102.htm SECOND AMENDED AND RESTATED SECURITY AGREEMENT, DATED JULY 24, 2017, BETWEEN MUSCLEPHARM CORPORATION AND RYAN DREXLER Exhibit 10.2 Second Amended and Restated Security Agreement This Second Amended and Restated Security Agreement (this “Agreement”), dated as of July 27, 2017, is entered into between Ryan Drexler, an individual (“Grantee”), and MusclePharm Corporation, a Nev |
|
| July 18, 2017 |
Exhibit 24 POWER OF ATTORNEY I hereby constitute and appoint each of Doug West and Ryan Drexler, signing singly, my true and lawful attorney-in-fact to: (1) execute on my behalf any Form 3 ? Initial Statement of Beneficial Ownership of Securities, Form 4 ? Statement of Changes of Beneficial Ownership of Securities, or Form 5 ? Annual Statement of Beneficial Ownership of Securities, including any a |
|
| July 13, 2017 |
MusclePharm CURRENT REPORT (Current Report/Significant Event) Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 July 7, 2017 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| July 13, 2017 |
MusclePharm Appoints New Members to its Board of Directors Blueprint Exhibit 99.1 MusclePharm Appoints New Members to its Board of Directors DENVER, July 13, 2017 - MusclePharm Corporation (OTCQB: MSLP) ("MusclePharm" or the "Company"), a scientifically-driven, performance lifestyle sports nutrition company, today announced two new appointments to its Board of Directors, including John J. Desmond, a certified public accountant with more than 40 years of p |
|
| July 10, 2017 |
MSLP / MusclePharm Corp. / WYNNEFIELD PARTNERS SMALL CAP VALUE LP I - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 4) Under the Securities Exchange Act of 1934 MUSCLEPHARM CORP. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 627335201 (CUSIP Number) Wynnefield Partners Small Cap Value, L.P. I 450 Seventh Avenue, Suite 509 New York, New York 10123 Attention: Mr. Nelson Obus Copy |
|
| June 12, 2017 |
MusclePharm FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 June 7, 2017 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| May 12, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2017 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53166 MusclePharm Cor |
|
| May 10, 2017 |
MusclePharm Reports 2017 First Quarter Financial Results Exhibit 99.1 MusclePharm Reports 2017 First Quarter Financial Results DENVER, May 10, 2017 - MusclePharm Corporation (MSLP) ("MusclePharm" or the "Company") (OTCQB: MSLP), a scientifically-driven, performance lifestyle sports nutrition company, today announced financial results for the quarter ended March 31, 2017. Operational and Financial Highlights for First Quarter 2017 (as compared to First Q |
|
| May 10, 2017 |
MusclePharm FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 10, 2017 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| May 4, 2017 |
MusclePharm SC 13D/A (Activist Acquisition of More Than 5% of Shares) CUSIP No. 627335201 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* MUSCLEPHARM CORP. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 627335201 (CUSIP Number) Ryan Charles Drexler c/o MusclePharm Corp. 4721 Ironton Street, Building A Denver, CO 80239 with |
|
| May 1, 2017 |
EXECUTIVE EMPLOYMENT AGREEMENT EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUT IVE EMPLOYMENT AGREEMENT ("Agreement") is made and entered into as of July 15, 2015 (the "Effective Date"), by and between MusclePharm Corporation, a Nevada Corporation (the "Company"), and Brian Casutto, an individual ("Executive"). |
|
| May 1, 2017 |
SEPARATION AGREEMENT AND GENERAL RELEASE SEPARATION AGREEMENT AND GENERAL RELEASE THIS SEPARATION AGREEMENT AND GENERAL RELEASE (the ?Agreement?) is made and entered into as of March 23, 2017 (the ?Effective Date?) by and between Brent Baker, an individual (?Executive?), and MusclePharm Corporation, a Nevada corporation (the ?Company?). |
|
| May 1, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year ended December 31, 2016 Commission File Number – 000-53166 MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 77-0664193 (State or other jurisdiction of incor |
|
| May 1, 2017 |
EXECUTIVE EMPLOYMENT AGREEMENT EXHIBIT 10.2 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT ("Agreement") is made and entered into as of January 1, 2016 (the "Effective Date"), by and between MusclePharm Corporation, a Nevada Corporation (the "Company"), and Brent Baker, an individual ("Executive"). The Company and Executive are sometimes referred to herein as a "party" or collectively as the "parties." RECIT |
|
| April 19, 2017 |
MSLP / MusclePharm Corp. / Amerop Holdings, Inc. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* MusclePharm Corporation (Name of Issuer) Common Shares (Title of Class of Securities) 627355-20-1 (CUSIP Number) April 10, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| March 22, 2017 |
MusclePharm FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 March 16, 2017 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| March 15, 2017 |
MusclePharm Issues Open Letter to Shareholders Exhibit 99.1 MusclePharm Issues Open Letter to Shareholders Providing Operational Update and Financial Highlights for the Full-Year 2016 PR Newswire DENVER, March 15, 2017 DENVER, March 15, 2017 /PRNewswire/ - MusclePharm Corporation (OTCQB: MSLP) ("MusclePharm" or the "Company"), a scientifically-driven, performance lifestyle sports nutrition company, today announced financial results for the fou |
|
| March 15, 2017 |
MusclePharm FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 March 15, 2017 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| March 15, 2017 |
To Annual Report Form 10-K For the Year ended December 31, 2016 Subsidiaries of the Registrant Exhibit 21.1 To Annual Report Form 10-K For the Year ended December 31, 2016 Subsidiaries of the Registrant Canada MusclePharm Enterprises Corporation (2012) Ontario, Canada Registered MP Holding Ireland, LLC (2014) Delaware LLC MusclePharm Holdings Ireland (2014) Ireland Registration Isle of Man Managed Company MusclePharm Ireland (2014) Ireland Registration MP DO Brazil Acquistion, LLC (2014) De |
|
| March 15, 2017 |
Exhibit 10.14 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT S |
|
| March 15, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year ended December 31, 2016 Commission File Number – 000-53166 MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 77-0664193 (State or other jurisdiction of incorporation or organiza |
|
| March 15, 2017 |
Exhibit 10.15 FIRST AMENDMENT TO CONVERTIBLE SECURED PROMISSORY NOTE This First Amendment to the Convertible Secured Promissory Note dated December 7, 2015 (the ?First Amendment?) is made as of January 14, 2017 (the ?First Amendment Effective Date?), by and between MusclePharm Corporation (the ?Company?) and Ryan Drexler (the ?Holder?). RECITALS A. The Company and the Holder entered into that cert |
|
| February 17, 2017 |
MSLP / MusclePharm Corp. / Schwarzenegger Arnold - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b) (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| February 8, 2017 |
ENDORSEMENT LICENSING AND CO-BRANDING AGREEMENT ENDORSEMENT LICENSING AND CO-BRANDING AGREEMENT This ENDORSEMENT LICENSING AND CO-BRANDING AGREEMENT is entered into on July 26, 2013 (the "Effective Date?) by and between Marine MP, LLC (?Lender?), for services of Arnold Schwarzenegger (?Endorser?), and Fitness Publications, Inc. |
|
| February 8, 2017 |
MusclePharm FORM 10-K/A (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year ended December 31, 2013 Commission File Number ? 000-53166 MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 77-0664193 (State or other jurisdiction of incor |
|
| January 27, 2017 |
MusclePharm FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 January 14, 2017 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| January 19, 2017 |
MSLP / MusclePharm Corp. / Amerop Holdings, Inc. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 MusclePharm Corporation (Name of Issuer) Common Shares (Title of Class of Securities) 627355-20-1 (CUSIP Number) January 4, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed |
|
| January 9, 2017 |
MusclePharm FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 January 4, 2017 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| December 19, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 December 15, 2016 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| December 2, 2016 |
EX-10.1 2 mslpex101.htm EMPLOYMENT AGREEMENT EXHIBIT 10.1 November 4, 2016 Mr. Peter Lynch 22060 East Arbor Drive Aurora CO, 80016 Dear Peter, We are pleased to offer you the position of Chief Financial Officer ("CFO"). Your annual compensation will be $300,000 paid on the standard pay cycle of the company. As a CFO, you will be a part of the bonus program with a yearly bonus potential of $100,000 |
|
| December 2, 2016 |
MusclePharm FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 December 2, 2016 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| December 2, 2016 |
EXHIBIT 99.1 December 2, 2016 MUSCLEPHARM ANNOUNCES HIRING OF NEW CHIEF FINANCIAL OFFICER DENVER, CO, December 1, 2016 /PRNewswire/ - MusclePharm Corporation (OTCQB: MSLP) ("MusclePharm" or the "Company"), a scientifically-driven, performance lifestyle sports nutrition company, today announced the appointment of Peter C. Lynch CPA as the Company?s new Chief Financial Officer, Principal Financial O |
|
| November 25, 2016 |
EXHIBIT 10.1 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (?Agreement?) is made and entered into as of the 18th day of November 2016 (the ?Amendment Date?), by and between MusclePharm Corporation, a Nevada corporation headquartered at 4721 Ironton Street, Building A, Denver, Colorado 80239 (?Company?) and Ryan Drexler (?Executive?). A |
|
| November 25, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 November 18, 2016 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| November 22, 2016 |
MSLP / MusclePharm Corp. / WYNNEFIELD PARTNERS SMALL CAP VALUE LP I - SC 13D/A Activist Investment UNITEDSTATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 3) Under the Securities Exchange Act of 1934 MUSCLEPHARM CORP. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 62733520 (CUSIP Number) Wynnefield Partners Small Cap Value, L.P. I 450 Seventh Avenue, Suite 509 New York, New York 10123 Attention: Mr. Nelson Obus Copy to |
|
| November 17, 2016 |
MSLP / MusclePharm Corp. / INI Buyer, Inc. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* MusclePharm Corporation (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 627335201 (CUSIP Number) November 7, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| November 17, 2016 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Act”), and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned with |
|
| November 15, 2016 |
MSLP / MusclePharm Corp. / Drexler Ryan Charles - SC 13D/A Activist Investment CUSIP No. 627335201 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* MUSCLEPHARM CORP. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 627335201 (CUSIP Number) Ryan Charles Drexler c/o MusclePharm Corp. 4721 Ironton Street, Building A Denver, CO 80239 with |
|
| November 9, 2016 |
EXHIBIT 99.1 MUSCLEPHARM REPORTS STRONG 2016 THIRD QUARTER FINANCIAL RESULTS Net Loss Reduced and Cash Increased as Company?s Strategic Restructuring Turns Corner DENVER, CO, November 9, 2016 /PRNewswire/ - MusclePharm Corporation (OTCQB: MSLP) ("MusclePharm" or the "Company"), a scientifically-driven, performance lifestyle sports nutrition company, today announced financial results for the quarte |
|
| November 9, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 November 9, 2016 Date of report (date of earliest event reported) MusclePharm Corporation (Exact name of registrant as specified in its charter) Nevada 000-53166 77-0664193 (State or other jurisdictions of incorporation or organization) (Commission File Number) (I. |
|
| November 9, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2016 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53166 MusclePharm |
